A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma

Cancer Investigation

Volumn 26, Issue 3, 2008, Pages 269-277

  Neyns, Bart ^a   Chaskis, Cristo ^a   Joosens, Eric ^b   Menten, Johan ^c   D'Hondt, Lionel ^d   Branle, Fabrice ^e   Sadones, Jan ^a   Michotte, Alex ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b Medical Oncology   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Centre Hospitalier Notre Dame et Reine Fabiola   (Belgium)

^e ERASME HOSPITAL   (Belgium)

Author keywords

Anaplastic; Astrocytoma; Oligoastrocytoma; Oligodendroglioma; Temozolomide

Indexed keywords

ALIZAPRIDE; CARBAMAZEPINE; COLONY STIMULATING FACTOR; DOMPERIDONE; GADOLINIUM; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MITOMYCIN C; NITROSOUREA; PHENYTOIN; TEMOZOLOMIDE; VALPROIC ACID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; ASTROCYTOMA; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INFECTION; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; COHORT STUDIES; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 40149093387     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701708393     Document Type: Article

References (29)

1. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Act. Neuropathol (Berl) 2007, 114(2), 97-109.
2. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol. 2001, 19(2), 509-518.
3. Levin, V.A.; Silver, P.; Hannigan, J.; Wara, W.M.; Gutin, P.H.; Davis, R.L.; Wilson, C.B. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 1990, 18(2), 321-324.
4. Yung, W.K.; Prados, M.D.; Yaya-Tur, R.; Rosenfeld, S.S.; Brada, M.; Friedman, H.S.; Albright, R.; Olson, J.; Chang, S.M.; O'Neill, A.M.; Friedman, A.H.; Bruner, J.; Yue, N.; Dugan, M.; Zaknoen, S.; Levin, V.A. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 1999, 17(9), 2762-2771.
5. Brada, M.; Hoang-Xuan, K.; Rampling, R.; Dietrich, P.Y.; Dirix, L.Y.; Macdonald, D.; Heimans, J.J.; Zonnenberg, B.A.; Bravo-Marques, J.M.; Henriksson, R.; Stupp, R.; Yue, N.; Bruner, J.; Dugan, M.; Rao, S.; Zaknoen, S. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 2001, 12(2), 259-266.
6. Chang, S.M.; Theodosopoulos, P.; Lamborn, K.; Malec, M.; Rabbitt, J.; Page, M.; Prados, M.D. Temozolomide in the treatment of recurrent malignant glioma. Cancer. 2004, 100(3), 605-611.
7. Everaert, E.; Neyns, B.; Joosens, E.; Strauven, T.; Branle, F.; Menten, J. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J. Neurooncol. 2004, 70(1), 37-48.
8. Yung, W.K.; Albright, R.E.; Olson, J.; Fredericks, R.; Fink, K.; Prados, M.D.; Brada, M.; Spence, A.; Hohl, R.J.; Shapiro, W.; Glantz, M.; Greenberg, H.; Selker, R.G.; Vick, N.A.; Rampling, R.; Friedman, H.; Phillips, P.; Bruner, J.; Yue, N.; Osoba, D.; Zaknoen, S.; Levin, V.A. A phase II study of temozolomide vs. procarbazine in patients with glioblastomamultiforme at first relapse. Br. J. Cancer. 2000, 83(5), 588-593.
9. Tolcher, A.W.; Gerson, S.L.; Denis, L.; Geyer, C.; Hammond, L.A.; Patnaik, A.; Goetz, A.D.; Schwartz, G.; Edwards, T.; Reyderman, L.; Statkevich, P.; Cutler, D.L.; Rowinsky, E.K. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer. 2003, 88(7), 1004-1011.
10. Michotte, A.; Neyns, B.; Chaskis, C.; Sadones, J.; In 't Veld, P. Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta. Neurol. Belg. 2004, 104(4), 148-153.
11. Macdonald, D.R.; Cascino, T.L.; Schold, S.C.; Cairncross, J.G. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 1990, 8(7), 1277-1280.
12. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343(19), 1350-1354.
13. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352(10), 997-1003.
14. Paz, M.F.; Yaya-Tur, R.; Rojas-Marcos, I.; Reynes, G.; Pollan, M.; Aguirre-Cruz, L.; Garcia-Lopez, J.L.; Piquer, J.; Safont, M.J.; Balana, C.; Sanchez-Cespedes, M.; Garcia-Villanueva, M.; Arribas, L.; Esteller, M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin. Cancer Res. 2004, 10(15), 4933-4938.
15. Tosoni, A.; Cavallo, G.; Ermani, M.; Scopece, L.; Franceschi, E.; Ghimenton, C.; Gardiman, M.; Pasetto, L.; Blatt, V.; Brandes, A.A. Is protracted low-dose temozolomide feasible in glioma patients? Neurology. 2006, 66(3), 427-429.
16. Brandes, A.A.; Tosoni, A.; Cavallo, G.; Bertorelle, R.; Gioia, V.; Franceschi, E.; Biscuola, M.; Blatt, V.; Crino, L.; Ermani, M. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br. J. Cancer. 2006, 95(9), 1155-1160.
17. Wick, A.; Felsberg, J.; Steinbach, J.P.; Herrlinger, U.; Platten, M.; Blaschke, B.; Meyermann, R.; Reifenberger, G.; Weller, M.; Wick, W. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol. 2007, 25(22), 3357-3361.
18. Wick, W.; Steinbach, J.P.; Kuker, W.M.; Dichgans, J.; Bamberg, M.; Weller, M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004, 62(11), 2113-2115.
19. Wick, W.; Weller, M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J. Clin. Oncol. 2005, 23(18), 4235-4236; author reply 4236.
20. Su, Y.B.; Sohn, S.; Krown, S.E.; Livingston, P.O.; Wolchok, J.D.; Quinn, C.; Williams, L.; Foster, T.; Sepkowitz, K.A.; Chapman, P.B. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. 2004, 22(4), 610-616.
21. Stupp, R.; Dietrich, P.-Y.; Ostermann Kraljevic, S.; Pica, A.; Maillard, I.; Maeder, P.; Meuli, R.; Janzer, R.; Pizzolato, G.; Miralbell, R.; Porchet, F.; Regli, L.; de Tribolet, N.; Mirimanoff, R.O.; Leyvraz, S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 2002, 20(5), 1375-1382.
22. van den Bent, M.J.; Delattre, J.; Brandes, A.A.; Taphoorn, M.J.; Hoang Xuan, K.; Bernsen, H.; Frenay, M.; Grisold, W.; Gorlia, T.; Lacombe, D. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma [abstract]. J. Clin. Oncol. 2005, 23(suppl), 114s. Abstract 1503.
23. Cairncross, G.; Seiferheld, W.; Shaw, E.; Jenkins, R.; Scheithauer, B.; Brachman, D.; Buckner, J.; Fink, K.; Souhami, L.; Curran, W. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02 [abstract]. J. Clin. Oncol. 2004, 23(suppl)(14s), 107. Abstract 1500.
24. Chahlavi, A.; Kanner, A.; Peereboom, D.; Staugaitis, S.M.; Elson, P.; Barnett, G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J. Neurooncol. 2003, 61(3), 267-273.
25. Buttolo, L.G.; Giunta, F.; Ferrari, V.D.; Grisanti, S.; Marini, G.; Mortini, P. Alternative schedules of adjuvant temozolomide in glioblastoma multiforme: a 6-year experience [abstract]. J. Clin. Oncol. 2006, 24(suppl)(18S), 60s. Abstract 1511.
26. Berrocal, A.; Pereze-Segura, P.; Gil, M.; Balana, C.; Yaya-Tur, R.; Rodriguez, J.; Reynes, G.; Garcia-Lopez, J.L.; Gallego, O.; Group, G.C. Phase II study of extended schedule temozolomide in refractory gliomas [abstract]. J. Clin. Oncol. 2006, 24(suppl)(18S), 62s. Abstract 1516.
27. Rizek, P.; Morrison, T.; Cashman, R.; Haller, T.; Perry, J. Low-dose temozolomide chemotherapy is active in recurrent malignant glioma, even following progression on conventional 5/28 day treatment: results of a practice audit [abstract]. Can. J. Neurol. Sci. 2004, 31(suppl 2)(3), S9. Abstract MED-6.
28. US National Institutes of Health. Radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma or gliosarcoma. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00304031?order=1. Accessed September 24, 2007.
29. European Organisation for Research and Treatment of Cancer: Brain tumour group: ongoing trials. Available at http://groups.eortc.be/brain/html/trials. html. Accessed September 24, 2007.